Flexibility using single-use System
Business Overview
SK bioscience has established a broad product portfolio and continues to invest in vaccine research,
which will be the driving force in the life science business in the future.
SK bioscience will develop premium vaccines based on superb technology and contribute promoting public health and contribute to the promotion of public health.
which will be the driving force in the life science business in the future.
SK bioscience will develop premium vaccines based on superb technology and contribute promoting public health and contribute to the promotion of public health.
Speed of Execution with Quality
SKYVAX Program
SK bioscience's proprietary product supply to
developing countries including LMIC
Platform Technology
- - Contractual development & manufacturing service
- - Technology transfer to local manufacture including
Manufacturing Versatility
Out-licensing and co-development
for US and Europe market for next decade
Market Leading Sales
/ Marketing Infrastructure
/ Marketing Infrastructure
- Joint sales and consignment production
based on leading position
in domestic vaccine market
Share Innovation
Key milestones of SK bioscience
-
2009
- Out-licensed CSL’s NBP601 (hemophilia drug), Korea’s first bio-pharmaceutical drug
-
2013
- Established partnership with IVI (International Vaccine Institute)
to collaborate on the development of a new typhoid conjugate vaccine
- Established partnership with IVI (International Vaccine Institute)
-
2014
- Established strategic partnership with Sanofi Pasteur for co-development of next-generation pneumococcal conjugate vaccine
-
2015
- Launched SKYCellflu, Korea’s first trivalent cell culture-derived influenza vaccine
-
2016
- Launched SKYCellflu Quadrivalent, world’s first quadrivalent cell culture-derived influenza vaccine
- Obtained approval for SKYPneumo, the first domestically produced PCV13 vaccine
-
2017
- Launched SKYZoster Inj.,
world’s second shingles vaccine - Signed agreement with international organization PATH to develop and produce pediatric enteritis vaccine
for developing countries
- Launched SKYZoster Inj.,
-
2018
- SKYVaricella Inj. licensed to market, Korea’s second chickenpox vaccine
- Signed agreement with Sanofi Pasteur to license out cell-culture technology for producing cell culture-based influenza vaccines
-
2019
- Gained WHO PQ for SKYCellflu prefilled syringe/ SKYCellflu Quadrivalent prefilled syringe (world’s first for cell-cultured influenza vaccine)
- Obtained WHO PQ for SKYVaricella Inj.
as world’s second
-
2020
- Selected GBP510 as WAVE2 by CEPI with GBP510 (COVID-19 vaccine)
- Initiated clinical trial for in-house produced COVID-19 vaccine (GBP510, NBP2001)
- Started Phase II clinical trial for the next-generation pneumococcal conjugate vaccine co-developed with Sanofi Pasteur
- Signed CMO agreement with AstraZeneca for COVID-19 vaccine
- Signed CDMO agreement with Novavax for COVID-19 vaccine
-
2021
- Initiated Phase III trial for COVID-19 vaccine candidate 'GBP510'
- Received fund to develop a vaccine candidate against COVID-19 (SARS-CoV-2) variants (CEPI)
- Submitted application for export permit of typhoid vaccine co-developed with IVI
- Signed licensing & purchase agreement for Novavax’s COVID-19 vaccine candidate (Novavax, KDCA)
- Obtained EU-GMP Certification for COVID-19 Vaccine Facilities
-
2022
- Published first TCFD report
- Received 'Grade A' rating on ESG Evaluation from the Korea Institute of Corporate Governance & Sustainability
- Donated to international Vaccine Institute to support global vaccine R&D
- Signed Advance Purchase Agreement of GBP510(KDCA)
- Agreed SKYvaricella distribution(PAHO)
- Achieved Turkish GMP Certification (TITCK)
- Achieved BLA of SKYTyphoid for export
- Published first ESG report
- Achieved BLA of SKYCovione (KMFDS)
-
2023
- Granted Emergency Use Listing by the World Health Organization (SKYCovione™)
- Achieved Marketing Auhorization from UK MHRA (SKYCovione™)
- Signed CMO agreement with MSD for Next-Generation Zaire Ebola Vaccine Candidate
- Achieved ISO 27001 Certification
- Received approval of world-first cell culture based quadrivalent influenza vaccine in Chile
- Received biologics license application approval of zoster vaccine in malaysia
- Initiate Submission of Phase III Study Investigational New Drug Amendment to the U.S. FDA of 21-Valent Pneumococcal Conjugate Vaccine Candidate (Sanofi)
-
2024
- Received A Grade in MSCI ESG Rating 2023
Business field
Process development
R&D center
- Various platform technologies for diverse vaccine types
- Process development team
- Evaluation/analysis team
- Bacterial vaccine team
- Viral vaccine team
- New project team
Development & commercial manufacturing
L HOUSE
- Pioneer in successful adaptation of ‘single-use system’ for vaccines on commercial scale
- ‘Multi-modular system’ for diverse vaccine types
-
-
Diverse platforms
-
Future expansion
Professional sales/marketing
Professional
- Specialized sales/marketing infrastructure make the company as a leader in the domestic vaccine market
- Various consignment production systems improve the convenience of vaccination
-
Unified system from licensing to selling
-
Specialized strategies for public/private market
-
Portfolio for all ages,
from infants to elderly